论文部分内容阅读
Objectives: To estimate the average cost per screening offer, cost per testin g episode and cost per chlamydia positive episode for an opportunistic chlamydia screening programme(including partner management), and to explore the uncertain ty of parameter assumptions, based on the costs to the healthcare system. Method s: A decision tree was constructed and parameterised using empirical data from a chlamydia screening pilot study and other sources. The model was run using base line data from the pilot, and univariate and multivariate sensitivity analyses w ere conducted. Results: The total estimated cost for offering screening over 12 months to 33 215 females aged 16- 24 was ￡ 493 412. The average cost (with par tner management) was ￡ 14.88 per screening offer (90% credibility interval (C I) 10.34 to 18.56), ￡ 21.83 per testing episode (90% CI 18.16 to 24.20)- , a nd ￡ 38.36 per positive episode (90% CI 33.97 to 42.25). The proportion of in dividuals accepting screening, the clinician (general practitioner/nurse) time a nd their relative involvement in discussing screening, the test cost, the time t o notify patients of their results, and the receptionist time recruiting patient s had the greatest impact on the outcomes in both the univariate and multivariate sensitivity analyses. Conclusions: Re sults from this costing study may be used to inform resource allocation for curr ent and future chlamydia screening programme implementation.
Objectives: To estimate the average cost per screening offer, cost per test in g episode and cost per chlamydia positive episode for an opportunistic chlamydia screening program (including partner management), and to explore the uncertainty ty of parameter assumptions, based on the costs to the healthcare system. Method s: A decision tree was constructed and parameterised using empirical data from a chlamydia screening pilot study and other sources. The model was run using base line data from the pilot, and univariate and multivariate sensitivity analyzes w ere conducted. The total estimated cost for offering screening over 12 months to 33 215 females aged 16- 24 was £ 493 412. The average cost (with par tner management) was £ 14.88 per screening offer (90% credibility interval (CI) 10.34 to 18.56) , £ 21.83 per testing episode (90% CI 18.16 to 24.20) -, a nd £ 38.36 per positive episode (90% CI 33.97 to 42.25). The proportion of in dividuals accepting screening, the cli nician (general practitioner / nurse) time a nd their relative involvement in discussing screening, the test cost, the time to notify patients of their results, and the receptionist time recruiting patient s had the greatest impact on the outcomes in both the univariate and multivariate sensitivity analyzes. Conclusions: Re sults from this costing study may be used to inform resource allocation for curr ent and future chlamydia screening program implementation.